Positive Final OS Results of Ph 3 JUPITER-02 Trial of Toripalimab as Treatment for Recurrent or mNPC announced February 22, 2023
Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible And Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer February 22, 2023
THIO + Atezolizumab or Pembrolizumab demonstrated Significantly Greater Tumor Inhibition February 22, 2023
Final Topline Data from Successful European Ph 1 monotherapy Trial of Annamycin in R/R AML patients announced February 22, 2023
New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma February 22, 2023
Opdivo® + CABOMETYX® shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in 1L Advanced RCC February 22, 2023
Updated Data Demonstrating Improved Outcomes from Niraparib + Abiraterone + Prednisone in 1L BRCA+ve metastatic CRPC announced February 22, 2023
Positive TALZENNA® and XTANDI® Combination Data from Ph 3 TALAPRO-2 Study Announced February 22, 2023
Adjuvant Opdivo Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk MIBC After 3 Yrs in CheckMate -274 Trial February 22, 2023
Final Results of Key Secondary OS Endpoint From Phase 3 PROpel Trial presented, OS endpoint not met February 22, 2023
KEYTRUDA + Chemo Significantly Improved OS vs chemo Alone in With HER2-Neg Gastric or GEJ Adenocarcinoma Patients Regardless of PD-L1 Expression February 22, 2023
Clinical Responses from the Ph 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer highlighted February 22, 2023
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% vs SoC in Earlier Lines of Therapy for R/R Multiple Myeloma in Ph 3 KarMMa-3 Study February 22, 2023
42-Patient Interim Data, with 90% ORR in R/R Multiple Myeloma at NXC-201 Therapeutic Dose from Ph 1 Expansion Trial presented February 22, 2023
Tecartus® CAR T-Cell Therapy Demonstrates OS Benefit In 3-Year Follow-Up Of Pivotal ZUMA-3 Trial In R/R B-Cell Acute Lymphoblastic Leukemia February 22, 2023
2023 EBMT-EHA: Encouraging initial safety and efficacy data for point-of-care manufactured GLPG5201 CAR-T in rrCLL presented February 22, 2023
FDA grants Fast Track designation for KIN-3248 for the treatment of patients with metastatic cholangiocarcinoma February 22, 2023
Regulatory update provided on the clinical development plan of Tedopi® in Ph 3 in monotherapy in advanced or mNSCLC after checkpoint inhibitor failure February 22, 2023
China NMPA Clears IND Application for Ph 1/2 Trial of FasTCAR-T GC012F for Treatment of R/R Multiple Myeloma February 22, 2023
FDA grants Orphan Drug Designation for the PRMT5 inhibitor JBI-778 for the treatment of Glioblastoma Multiforme (GBM) February 22, 2023
Refusal to File Letter issued from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma February 22, 2023
FDA Clears IND Application for Ph 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of R/R Multiple Myeloma February 22, 2023
Orphan Drug Designation Granted to Adze-1.17-CD40L for the treatment of Malignant Glioma February 22, 2023
